Zhejiang Poly Pharm Co., Ltd. secured FDA approval for its generic oral formulation of Brivaracetam, granting the manufacturer a competitive foothold in the neurological market and the ability to offer a lower-cost alternative to branded therapies.
Zhejiang Poly Pharm Co., Ltd. secured FDA approval for its generic oral formulation of Brivaracetam, granting the manufacturer a competitive foothold in the neurological market and the ability to offer a lower-cost alternative to branded therapies.